Retatrutide – 10mg
Research-grade Retatrutide (LY-3437943), a synthetic triple GLP-1/GIP/glucagon receptor agonist peptide studied for advanced metabolic research. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry. CAS 2381089-83-2.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
Retatrutide has generated significant interest in the peptide research community as a triple-agonist compound. It is sometimes called "GLP-3" informally due to its three-receptor mechanism. Researchers frequently compare it alongside Semaglutide (mono-agonist) and Tirzepatide (dual-agonist) to study multi-receptor pharmacology. Durham Peptides carries all three compounds.
BENEFITS
Triple receptor activation — studied for simultaneous GLP-1, GIP, and glucagon engagement
Metabolic research — explored in Phase 2 clinical trials with notable body composition results
Glucagon component — linked to thermogenesis and energy expenditure pathways
Next-generation compound — investigated as an advancement over dual-agonist approaches
Comparative pharmacology — assessed alongside mono and dual agonists in research settings
WHAT RESEARCHERS LOOK AT
Triple agonist binding affinity across GLP-1, GIP, and glucagon receptors
Additive effects of glucagon receptor activation on energy expenditure
Dose-response and tolerability profiling from clinical trial data
Comparative outcomes vs tirzepatide and semaglutide
Pharmacokinetic profiling and receptor selectivity